Targeted strategies in the treatment of primary gastric lymphomas: From rituximab to recent insights into potential new drugs

Current Medicinal Chemistry

Volumn 21, Issue 8, 2014, Pages 1005-1016

  Merchionne, Francesca ^a   Iacopino, Pasquale ^a   Minoia, Carla ^a   Iacobazzi, Angela ^a   Rana, Antonio ^a   Serratì, Simona ^a   De Tullio, Giacoma ^a   Loseto, Giacomo ^a   Lapietra, Angela ^a   Lucarelli, Annunziata ^b   Guarini, Attilio ^a  

^a NATIONAL CANCER CENTRE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Bortezomib; Diffuse large B cell lymphoma; Eradication therapy; Helicobacter pylori; MALT lymphoma; Pathogenesis; Rituximab; Stomach; Targeted therapies

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BORTEZOMIB; DARINAPARSIN; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; PROTEIN BCL 10; PROTEIN BCL 3; PROTEINASE INHIBITOR; RITUXIMAB;

ANTIBODY DEPENDENT LEUKOCYTE CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BACTERIAL CLEARANCE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG EFFICACY; GENE EXPRESSION PROFILING; HELICOBACTER INFECTION; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PATIENT CARE; PRIMARY GASTRIC NON HODGKIN LYMPHOMA; PROTEIN EXPRESSION; STOMACH LYMPHOMA; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; PROGNOSIS; STOMACH; STOMACH NEOPLASMS;

EID: 84896356183     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990235     Document Type: Article

References (63)

1. Psyrri, A.; Papageorgiou, S.; Economopoulos, T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann. Oncol., 2008, 19, 1992-1999.
2. Howell, J.M.; Auer-Grzesiak, I.; Zhang, J.; Andrews, C.N.; Stewart, D.; Urbanski, S.J. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can. J. Gastroenterol., 2012, 26, 452-456.
3. Koch, P.; del Valle, F.; Berdel, W.E.; Willich, N.A.; Reers, B.; Hiddemann, W.; Grothaus-Pinke, B.; Reinartz, G.; Brockmann, J.; Temmesfeld, A.; Schmitz, R.; Rübe, C.; Probst, A.; Jaenke, G.; Bodenstein, H.; Junker, A.; Pott, C.; Schultze, J.; Heinecke, A.; Parwaresch, R.; Tiemann, M.; German Multicenter Study Group. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J. Clin. Oncol., 2001, 19, 3861-3873.
4. Rizvi, M.A.; Evens, A.M.; Tallman, M.S.; Nelson, B.P.; Rosen, S.T. T-cell non-Hodgkin lymphoma. Blood, 2006, 107, 1255-1264.
5. Bautista-Quach, M.A.; Ake, C.D.; Chen, M.; Wang, J. Gastrointestinal lymphomas: morphology, immunophenotype and molecular features. J. Gastrointest. Oncol., 2012, 3, 209-225.
6. Thomas, J.A.; Allday, M.J.; Crawford, D.H. Epstein-Barr virusassociated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res., 1991, 57,329-380.
7. Isaacson, P.; Wright, D.H. Malignant lymphoma of mucosaassociated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer, 1983, 52, 1410-1416.
8. Isaacson, P.G. The MALT lymphoma concept updated. Ann. Oncol., 1995, 6, 319-320.
9. Bende, R.J.; van Maldegem, F.; van Noesel, C.J.M. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica, 2009, 94, 1109-1123.
10. Isaacson, P.G.; Du, M.Q. MALT-lymphoma: from morphology to molecules. Nat. Rev. Cancer, 2004, 4, 644-653.
11. Bende, R.J.; Aarts, W.M.; de Jong, D.; Pals, S.T.; van Noesel, C.J. Among B-cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med., 2005, 201,1229-1241.
12. Craig, V.J.; Arnold, I.; Gerke, C.; Huynh, M.Q.; Wündisch, T.; Neubauer, A.; Renner, C.; Falkow, S.; Müller, A. Gastric MALT lymphoma B cells express polireactive, somatically mutated immunoglobulins. Blood, 2010, 115, 581-591.
13. Farinha, P.; Gascoyne, R.D. Molecular pathogenesis of mucosaassociated lymphoid tissue lymphoma. J. Clin. Oncol., 2005, 23, 6370-6378.
14. Ferrucci, P.F.; Zucca, E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br. J. Haematol., 2006, 136, 521-538.
15. Hu, S.; Du, M.Q.; Park, S.M.; Alcivar, A.; Qu, L.; Gupta, S.; Tang, J.; Baens, M.; Ye, H.; Lee, T.H.; Marynen, P.; Riley, J.L.; Yang, X. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J. Clin. Invest., 2006, 116, 174-181.
16. Sagaert, X.; de Paepe, P.; Libbrecht, L.; Vanhentenrijk, V.; Verhoef, G.; Thomas, J.; Wlodarska, I.; De Wolf-Peeters, C. Forkhead Box Protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J. Clin. Oncol., 2006, 24, 2490-2497.
17. Peng, H.; Du, M.; Diss, T.C.; Isaacson, P.G.; Pan, L. Genetic evidence for a clonal link between low and high-grade components in gastric MALT B-cell lymphoma. Histopatology, 1997, 30, 425-429.
18. Kuo, S.H.; Chen, L.T.; Yeh, K.H.; Wu, M.S.; Hsu, H.C.; Yeh, P.Y.; Mao, T.L.; Chen, C.L.; Doong, S.L.; Lin, J.T.; Cheng, A.L. Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-indipendent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. J. Clin. Oncol., 2004, 22, 3491-3497.
19. Ye, K.H.; Kuo, S.H.; Chen, L.T.; Mao, T.L.; Doong, S.L.; Wu, M.S.; Hsu, H.C.; Tzeng, Y.S.; Chen, C.L.; Lin, J.T.; Cheng, A.L. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-indipendent status of low-grade gastric gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood, 2005, 106, 1037-1041.
20. Kuo, S.H.; Chen, L.T.; Wu, M.S.; Kuo, K.T.; Yeh, K.H.; Doong, S.L.; Yeh, P.Y.; Hsu, H.C.; Tzeng, Y.S.; Lin, C.W.; Lin, J.T.; Cheng, A.L. Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach - significance of tumour cell clonality and BCL10 expression. J. Pathol., 2007, 211, 296-304.
21. Craig, V.J.; Cogliatti, S.; Imig, B.J.; Renner, C.; Neuenschwander, S.; Rehrauer, H.; Schlapbach, R.; Dirnhofer, S.; Tzankov, A.; Müller, A. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood, 2011, 117, 6227-6236.
22. Nakamura, S.; Ye, H.; Bacon, C.M.; Goatly, A.; Liu, H.; Kerr, L.; Banham, A.H.; Streubel, B.; Yao, T.; Tsuneyoshi, M.; Savio, A.; Takeshita, M.; Dartigues, P.; Ruskoné-Fourmestraux, A.; Matsumoto, T.; Iida, M.; Du, M.Q. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. Clin. Cancer Res., 2008, 14, 3002-3010.
23. Ponzoni, M.; Ferreri, A.J.M.; Pruneri, G.; Pozzi, B.; Dell'Oro, S.; Pigni, A.; Pinotti, G.; Villa, E.; Freschi, M.; Viale, G.; Capella, C. Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in Stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. Int. J. Cancer, 2003, 106, 288-291.
24. Chen, Y.W.; Hu, X.T.; Liang, A.C.; Au, W.Y.; So, C.C.; Wong, M.L.; Shen, L.; Tao, Q.; Chu, K.M.; Kwong, Y.L.; Liang, R.H.; Srivastava, G. High BCL-6 expression predicts better prognosis, independent of BCL-6 translocation status, translocation partner or BCL-6 deregulating mutations, in gastric lymphoma. Blood, 2006, 108, 2373-2383.
25. Wotherspoon, A.C.; Doglioni, C.; Diss, T.C.; Pan, L.; Moschini, A.; de Boni, M.; Isaacson, P.G. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 1993, 342, 575-577.
26. Stolte, M.; Bayerdörffer, E.; Morgner, A.; Alpen, B.; Wündisch, T.; Thiede, C.; Neubauer, A. Helicobacter and gastric MALT lymphoma. Gut, 2002, 50, Suppl 3, III19-III24.
27. Zullo, A.; Hassan, C.; Cristofari, F.; Andriani, A.; De Francesco, V.; Ierardi, E.; Tomao, S.; Stolte, M.; Morini, S.; Vaira, D. Effects of Helicobacter pylori eradication on early stage gastric mucosaassociated lymphoid tissue lymphoma. Clin. Gastroenterol. Hepatol., 2010, 8, 105-110.
28. Zullo, A.; Hassan, C.; Andriani, A.; Cristofari, F.; De Francesco, V.; Ierardi, E.; Tomao, S.; Morini, S.; Vaira, D. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am. J. Gastroenterol., 2009, 104, 1932-1937.
29. Chen, L.T.; Lin, J.T.; Tai, J.J.; Chen, G.H.; Yeh, H.Z.; Yang, S.S.; Wang, H.P.; Kuo, S.H.; Sheu, B.S.; Jan, C.M.; Wang, W.M.; Wang, T.E.; Wu, C.W.; Chen, C.L.; Su, I.J.; Wang-Peng, J.; Cheng, A.L. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J. Natl. Cancer, 2005, 97, 1345-1353.
30. Kuo, S.H.; Yeh, K.H.; Wu, M.S.; Lin, C.W.; Hsu, P.N.; Wang, H.P.; Chen, L.T.; Cheng, A.L. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood, 2012, 119, 4838-4844.
31. Ferreri, A.J.; Govi, S.; Raderer, M.; Mulè, A.; Andriani, A.; Caracciolo, D.; Devizzi, L.; Ilariucci, F.; Luminari, S.; Viale, E.; Müllauer, L.; Dell'Oro, S.; Arcidiacono, P.G.; Ponzoni, M.; Patti, C. Helicobacter pylori eradication as exclusive treatment for limited stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood, 2012, 120, 3858-3860.
32. Conconi, A.; Martinelli, G.; Thieblemont, C.; Ferreri, A.J.; Devizzi, L.; Peccatori, F.; Ponzoni, M.; Pedrinis, E.; Dell'Oro, S.; Pruneri, G.; Filipazzi, V.; Dietrich, P.Y.; Gianni, A.M.; Coiffier, B.; Cavalli, F.; Zucca, E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 2003, 102, 2741-2745.
33. Martinelli, G.; Laszlo, D.; Ferreri, A.J.; Pruneri, G.; Ponzoni, M.; Conconi, A.; Crosta, C.; Pedrinis, E.; Bertoni, F.; Calabrese, L.; Zucca, E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti Helicobacter pylori therapy. J. Clin. Oncol., 2005, 23, 1979-1983.
34. Raderer, M.; Wohrer, S.; Streubel, B.; Drach, J.; Jager, U.; Turetschek, K.; Troch, M.; Puspok, A.; Zielinski, C.C.; Chott, A. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology, 2006, 70, 411-417.
35. Salar, A.; Domingo-Domènech, E.; Estany, C.; Canales, M.; Gallardo, F.; Servitge, O.; Fraile, G.; Montalbàn, C. Combination therapy with rituximab and intravenous or oral fludarabine in the firstline, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer, 2009, 115, 5210-5217.
36. Zucca, E.; Conconi, A.; Laszlo, D.; Lòpez-Guillermo, A.; Bouabdallah, R.; Coiffier, B.; Sebban, C.; Jardin, F.; Vitolo, U.; Morschhauser, F.; Pileri, S.A.; Copie-Bergman, C.; Campo, E.; Jack, A.; Floriani, I.; Johnson, P.; Martelli, M.; Cavalli, F.; Martinelli, G.; Thieblemont, C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J. Clin. Oncol., 2013,31, 565-572.
37. Troch, M.; Kiesewetter, B.; Willenbacher, W.; Willenbacher, E.; Zebisch, A.; Linkesch, W.; Fridrik, M.; Müllauer, L.; Greil, R.; Raderer, M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue: a phase II study by Srbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica, 2013, 98, 264-268.
38. Wöhrer, S.; Püspök, A.; Drach, J.; Hejna, M.; Chott, A.; Raderer, M. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann. Oncol., 2004, 15, 1086-1090.
39. Kobayashi, Y.; Hatta, Y.; Hojo. A.; Kura, Y.; Uchino, Y.; Takahashi, H.; Kiso, S.; Hirabayashi, Y.; Yagi, M.; Kodaira, H.; Kurita, D.; Tanaka, T.; Miura, K.; Iriyama, N.; Kobayashi, S.; Sawada, U.; Sugitani, M.; Takeuchi, J. Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Exp. Ther. Med., 2012, 3, 304-308.
40. Leopardo, D.; Di Lorenzo, G.; De Renzo, A.; Federico, P.; Luponio, S.; Buonerba, C.; Matano, E.; Merola, G.; Imbimbo, M.; Montesarchio, E.; Rea, A.; Merola, M.C.; De Placido, S.; Palmieri, G. Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. World J. Gastroenterol., 2010, 16, 2526-2530
41. Zhang, J.; Li, G.; Yang, H.; Liu, X.; Cao, J. Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. Leuk. Lymphoma, 2012, 53, 2175-2181.
42. Tanaka, T.; Shimada, K.; Yamamoto, K.; Hirooka, Y.; Niwa, Y.; Sugiura, I.; Kitamura, K.; Kosugi, H.; Kinoshita, T.; Goto, H.; Nakamura, S. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Ann. Hematol., 2012, 91, 383-390.
43. Sohn, B.S.; Kim, S.M.; Yoon, D.H.; Kim, S.; Lee, D.H.; Kim, J.H.; Lee, S.W.; Huh, J.; Suh, C. The comparison between CHOP and RCHOP in primary gastric diffuse large B cell lymphoma. Ann. Hematol., 2012, 91, 1731-1739.
44. Morschhauser, F.; Radford, J.; Van Hoof, A.; Vitolo, U.; Soubeyran, P.; Tilly, H.; Huijgens, P.; Kolstad, A.; d'Amore, F.; Gonzalez Diaz, M.; Petrini, M.; Sebban, C.; Zinzani, P.L.; van Oers, M.H.J.; van Putten, W.; Bischof-Delaloye, A.; Rohatiner, A.; Salles, G.; Kuhlmann, J.; Hagenbeek, A. Phase III trial of consolidation therapy with Yttrium-90-Ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol., 2008, 26, 5156-5164.
45. Witzig, T.E.; Gordon, L.I.; Emmnouilides, C.; Wiseman, G.A.; Dimitrov, G.; Ding, E.; Lee, D.D.; White, C.A. Safety and efficacy of Zevalin in for patients with Mucosa Associated Lymphoid Tissue (MALT) Lymphoma. Blood, 2001, 98, 254b.
46. Vanazzi, A.; Ferrucci, P.F.; Grana, C.M.; Pruneri, G.; Crosta, C.; Pinto, A.; Chinol, M.; Calabrese, L.; Paganelli, G.; Martinelli, G. Efficacy of 90Y-Ibritumomab tiuxetan in relapsed or refractory primary gastric non Hodgkin Lymphoma. Blood, 2008, 112, 3063.
47. Hoffmann, M.; Troch, M.; Eidherr, H.; Traub-Weidinger, T.; Jonak, C.; Muellauer, L.; Raderer, M. 90Y-Ibritumomab tiuxetan (Zevalin) in heavely pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk. Lymphoma, 2011, 52, 42-45.
48. Kane, R.C.; Bross, P.F.; Farrel, A.T.; Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prio therapy. Oncologist, 2003, 8, 508-513.
49. Pham, L.V.; Tamayo, A.T.; Yoshimura, L.P.; Lo, P.; Ford, R.J. Inhibition of constitutive NF-kB activation in mantle cell lymphoma B-cells leads to induction of cell cycle arrest and apoptosis. J. Immunol., 2003, 171, 88-95.
50. Pérez-Galàn, P.; Roué, G.; Villamor, N.; Montserrat, E.; Campo, E.; Colomer, D. The proteasome inhibitor bortezomib induces apoptosis in mantle cell lymphoma through of generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107, 257-264.
51. Pham, L.; Tamayo, A.; Lo, P. Anti-tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood, 2001, 98,1945.
52. Goy, A.; Younes, A.; McLaughlin, P.; Pro, B.; Romaguera, J.E.; Hagemeister, F.; Fayad, L.; Dang, N.H.; Samaniego, F.; Wang, M.; Broglio, K.; Samuels, B.; Gilles, F.; Sarris, A.H.; Hart, S.; Trehu, E.; Schenkein, D.; Cabanillas, F.; Rodriguez, A. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell lymphoma. J. Clin. Oncol., 2005, 23, 667-675.
53. Troch, M.; Jonak, C.; Müllauer, L.; Püspök, A.; Formanek, M.; Hauff, W.; Zielinski, C.;, Chott, A.; Raderer, M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica, 2009, 94, 738-742.
54. Di Bella, N.; Taetle, R.; Kolibaba, K.; Boyd, T.; Raju, R.; Barrera, D.; Cochran, E.W.; Dien, P.Y. Jr; Lyons, R.; Schlegel, P.J.; Vukelja, S.J.; Boston, J.; Boehm, K.A.; Wang, Y.; Asmar, L. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood, 2010, 115, 475-480.
55. Conconi, A.; Martinelli, G.; Lopez-Guillermo, A.; Zinzani, P.L.; Ferreri, A.J.M.; Rigacci, L.; Devizzi, L.; Vitolo, U.; Luminari, S.; Cavalli, F.; Zucca, E. Clinical activity of bortezomib in relapsed/ refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann. Oncol., 2011, 22, 689-695.
56. de Vos, S.; Goy, A.; Dakhil, S.R.; Saleh, M.N.; McLaughlin, P.; Belt, R.; Flowers, C.R.; Knapp, M.; Hart, L.; Patel-Donnelly, D.; Glenn, M.; Gregory, S.A.; Holladay, C.; Zhang, T.; Boral, A.L. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J. Clin. Oncol., 2009, 27, 5023-5030.
57. Merchionne, F.; Perosa, F.; Dammacco, F. New therapies in multiple myeloma. Clin. Exp. Med., 2007, 7, 83-97.
58. Kiesewetter, B.; Troch, M.; Dolak, W.; Müllauer, L.; Lukas, J.; Zielinski, C.C.; Raderer, M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma). Haematologica, 2013, 96, 353-356.
59. Hosein, P.J.; Craig, M.D.; Tallman, M.S.; Boccia, R.V.; Hamilton, B.L.; Lewis, J.J.; Lossos, I.S. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non- Hodgkin's lymphoma. Am. J. Hematol., 2012, 87, 111-114.
60. Kuo, S.H.; Yeh, P.Y.; Chen L.T.; Wu, M.S.; Lin, C.W.; Yeh, K.H.; Tzeng, Y.S.; Chen, J.Y.; Hsu, P.N.; Lin, J.T.; Cheng, A.L. Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-indipendent growth of gastric dif fuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood, 2008, 112: 2927-2934.
61. Munari, F.; Lonardi, S.; Cassatella, M.A.; Doglioni, C.; Cangi, M.G.; Amedei, A.; Facchetti, F.; Eishi, Y.; Rugge, M.; Fassan, M.; de Bernard, M.; D'Elios, M.M.; Vermi, W. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood, 2011, 117, 6612-6616.
62. McAllister - Lucas, L.M.; Baens, M.; Lucas, P.C. MALT1 protease: a new therapeutic target in B lymphoma and beyond ? Clin. Cancer Res., 2011, 17, 6623-6631.
63. Ansell, S.M.; Akasaka, T.; McPhail, E.; Manske, M.; Braggio, E.; Price-Troska, T.; Ziesmer, S.; Secreto, F.; Fonseca, R.; Gupta, M.; Law, M.; Witzig, T.E.; Dyer, M.J.; Dogan, A.; Cerhan, J.R.; Novak, A.J. t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood, 2012, 120: 3949-3957.